What is the current market size?

The Pemetrexed Injection market size was valued at approximately USD 1.2 billion in 2023, driven by rising oncology drug demand and therapeutic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by expanding indications and growing cancer prevalence.

What are the key growth drivers?

Key drivers include rising incidence of non-small cell lung cancer, increased adoption of targeted therapies, and improved reimbursement policies.

What challenges does the market face?

Challenges include high treatment costs, adverse side effects limiting patient compliance, and competition from generic alternatives.

Which regions lead the market?

North America dominates the Pemetrexed Injection market, followed by Europe, due to advanced healthcare infrastructure and high R&D investments.

Who are the top companies?

Leading players include Eli Lilly (Alimta), Sanofi, and Teva Pharmaceuticals, with strategic focus on product differentiation and partnerships.

What are future opportunities?

Future growth opportunities lie in combination therapies, expansion into emerging markets, and development of biosimilars to reduce costs.

How is technology impacting innovation?

Advancements in drug delivery systems and personalized medicine are enhancing Pemetrexed Injection efficacy and patient adherence rates.

What is the regulatory environment like?

Regulatory approvals by FDA and EMA ensure safety, but stringent requirements for clinical trials challenge market entry for new players.

Pemetrexed Injection Growth Opportunities & Strategic Forecast 2033

Pemetrexed Injection by Application (Non Squamous Non-Small Cell Lung Cancer, Squamous Cell Non-Small Cell Lung Cancer), by Types (0.5g Bottle, 0.2g Bottle), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Pemetrexed Injection Market Size | CAGR 8.5 Forecast 2033

Pemetrexed Injection Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pemetrexed Injection Market Overview

The Pemetrexed Injection market encompasses the global demand for this antineoplastic agent, primarily used in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. As a cornerstone of chemotherapy regimens, its relevance is underscored by its role in improving survival rates and quality of life for oncology patients. The Pemetrexed Injection market size was valued at approximately $1.2 billion in 2025, with a projected growth outlook of 7.2% CAGR through 2033, driven by rising cancer prevalence and advancements in combination therapies. Industry expansion is further fueled by regulatory approvals for new formulations and expanding indications.

Loading chart…

Key macro drivers include the increase in lung cancer incidence—notably in aging populations—and the adoption of precision oncology strategies integrating pemetrexed with immunotherapies. Regulatory tailwinds, such as WHO prequalification for biosimilars, are accelerating market access in emerging economies. North America remains the largest regional market due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, buoyed by rising awareness and government-funded cancer screening programs. Strategic partnerships to develop extended-release variants and reduce dosing frequency are further poised to reshape competitive dynamics.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eagle Pharmaceuticals; AuroMedics Pharma; Teva Pharmaceutical Industries; Taro Pharma; Seacross Pharmaceuticals; Simcere Pharmaceutical Group; Qilu Pharmaceutical; Pfizer; Jiangsu Anda Pharmaceutical; Yangtze River Pharmaceutical Group; Hansoh Pharmaceutical Group Company; Nanjing Pharmaceutical Factory; DEYAO PHARMA; Vianex S.A.-Plant C; Hainan Jinrui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Pemetrexed Injection market is shaped by evolving clinical needs, regulatory landscapes, and competitive dynamics. This section evaluates key drivers, restraints, and strategic inflection points influencing the Pemetrexed Injection market size and long-term growth forecast.

Growth Drivers2 items

Rising prevalence of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, which are primary indications for pemetrexed, is fueling demand. Advanced diagnostic tools and early detection initiatives are further boosting treatment uptake.

Growing adoption of pemetrexed in combination therapies with immunotherapy agents like pembrolizumab, enhancing treatment efficacy and expanding its therapeutic applications in oncology.

Restraints2 items

High treatment costs and limited insurance coverage in emerging markets are restricting patient access, particularly in regions with fragmented healthcare reimbursement systems.

Stringent regulatory requirements for drug approval and post-market surveillance, which delay product launches and increase compliance expenditures for manufacturers.

Opportunities2 items

Expansion into untapped markets in Asia-Pacific and Latin America, driven by improving healthcare infrastructure and rising awareness among oncologists about pemetrexed’s role in precision medicine.

Development of novel formulations, such as lyophilized pemetrexed, to enhance drug stability and reduce infusion times, addressing unmet needs in outpatient care settings.

Challenges2 items

Emergence of biosimilars and generic alternatives, which threaten market share by offering cost-effective substitutes without compromising on efficacy.

Pricing pressures from government payers and managed care organizations, particularly in the U.S. and EU, compressing profit margins for branded pemetrexed products.

Market Segmentation

Loading chart…

Pemetrexed Injection segmentation by application reveals distinct demand drivers. Non-Small Cell Lung Cancer (NSCLC) dominates the market, accounting for 65% of applications due to its first-line use in combination therapies. Malignant Pleural Mesothelioma, the second-largest segment at 35%, relies heavily on pemetrexed as a monotherapy in advanced stages. These applications are shaped by treatment guidelines, with NSCLC benefiting from high incidence rates and mesothelioma driven by limited alternative therapies. The oncology focus underscores the product’s role in addressing unmet needs in refractory cancers, directly influencing market size through clinical adoption rates.

The market taxonomy of Pemetrexed Injection types divides into Brand and Generics. The brand segment holds a 55% market share, anchored by Alimta’s established safety profile and oncologists’ prescribing habits. Generics, representing 45%, are expanding due to cost-effectiveness and post-patent expiration accessibility. Regulatory approvals and pricing dynamics differentiate these segments: brands maintain premium pricing, while generics compete on affordability. This dichotomy reflects the tension between innovation and cost containment in oncology markets, with generics poised to grow as reimbursement pressures intensify globally.

Pemetrexed Injection Segmentation Breakdown6 items

Application

Non Squamous Non-Small Cell Lung Cancer

Squamous Cell Non-Small Cell Lung Cancer

Types

0.5g Bottle

0.2g Bottle

Regional Insights

Loading chart…

North America dominates the Pemetrexed Injection market, accounting for ~35% share, driven by advanced oncology infrastructure, high adoption of premium therapies, and robust R&D investments. Key drivers include FDA approvals for combination therapies, a large non-small cell lung cancer patient pool, and strong reimbursement policies. The Pemetrexed Injection market growth in this region is further fueled by strategic partnerships between biopharma firms and healthcare providers.

Europe holds ~25% of the market, supported by aging demographics, stringent regulatory frameworks ensuring drug quality, and expanding access to targeted cancer treatments. Germany and France lead due to high healthcare expenditures and proactive EU policies. The region’s regional forecast shows steady growth, albeit constrained by budgetary pressures on healthcare systems.

Asia Pacific (APAC) is the fastest-growing region, projected to expand at a CAGR of 12% through 2030. Factors include rising cancer incidence, government initiatives to improve oncology care (e.g., India’s Jan Aushadhi Scheme), and increasing affordability of biosimilars. Infrastructure upgrades in China and South Korea are accelerating Pemetrexed Injection market growth.

Regional Constraints and Opportunities2 items

Latin America (~15%) faces fragmented healthcare access but benefits from Brazil’s public-sector procurement policies.

Middle East & Africa (~5%) lags due to underdeveloped oncology ecosystems but sees incremental growth from UAE and South Africa’s healthcare modernization projects.

Competitive Landscape

The Pemetrexed Injection competitive landscape is moderately consolidated, with a mix of global and regional players vying for market share. Key manufacturers leverage pricing strategies, regulatory compliance, and distribution networks to differentiate offerings. While global firms focus on broad patent portfolios and cross-border approvals, regional players emphasize localized production and cost-competitive pricing to capture emerging market demand. Certifications like FDA or EMA approval remain critical for market access, particularly in developed economies. Strategic emphasis on biosimilar development and generic equivalents is intensifying price competition, especially in mature markets where branded products face patent expiration.

Competitive strategies center on vertical integration, OEM partnerships, and geographic expansion to mitigate margin pressures from commoditization risks. Companies are prioritizing R&D for formulation innovations and dosage optimization to extend product life cycles. A significant challenge lies in managing supply chain disruptions for active pharmaceutical ingredients, particularly for players reliant on China and India for raw material sourcing. Compliance costs for evolving oncology drug regulations also strain smaller firms, creating acquisition opportunities for larger entities with established quality assurance frameworks.

Eagle Pharmaceuticals: regional expansion in Latin America

AuroMedics Pharma: cost advantages through India-based manufacturing

Teva Pharmaceutical Industries: OEM tie-ups for generic formulations

Taro Pharma: product launches targeting oncology niche segments

Seacross Pharmaceuticals: vertical integration for supply chain control

Simcere Pharmaceutical Group: innovation pipeline for proprietary delivery systems

Key Pemetrexed Injection Companies15 items

Eagle Pharmaceuticals

AuroMedics Pharma

Teva Pharmaceutical Industries

Taro Pharma

Seacross Pharmaceuticals

Simcere Pharmaceutical Group

Qilu Pharmaceutical

Pfizer

Jiangsu Anda Pharmaceutical

Yangtze River Pharmaceutical Group

Hansoh Pharmaceutical Group Company

Nanjing Pharmaceutical Factory

DEYAO PHARMA

Vianex S.A.-Plant C

Hainan Jinrui Pharmaceutical

Market Ecosystem

The Pemetrexed Injection ecosystem spans upstream development, midstream production, and downstream distribution. Value is generated through the integration of specialized raw materials, advanced manufacturing processes, and targeted delivery to healthcare providers. Regulatory frameworks and clinical validation anchor the system, ensuring compliance while enabling market access.

Raw material/component suppliers — supply active pharmaceutical ingredients and excipients for formulation

OEMs/Manufacturers — produce pemetrexed injection under Good Manufacturing Practice (GMP) standards

Technology providers — develop proprietary formulation or lyophilization solutions for stability

Packaging suppliers — provide sterile vials and safety-closure systems meeting pharmacopeia requirements

Distributors/Channel partners — manage cold-chain logistics and inventory to hospitals and pharmacies

Healthcare providers — administer treatment in oncology departments following clinical guidelines

Regulators/Standards bodies — enforce approval pathways and post-market pharmacovigilance protocols

Control points reside with regulators setting approval benchmarks and manufacturers securing raw material supply. Dependency risks include delays in regulatory submissions or disruptions to active ingredient sourcing. Switching costs are high for distributors managing validated supply chains, while interoperability requirements for electronic prescribing systems influence adoption rates across care settings.

Recent Industry Insights

The Pemetrexed Injection industry trends over the past 18 months reflect a dynamic landscape driven by innovation and strategic consolidation. Key partnerships have emerged, such as the 2023 collaboration between Eli Lilly and a biotech firm to advance next-generation formulation technologies, aiming to improve drug stability and patient outcomes. Mergers and acquisitions activity has intensified, with Sanofi acquiring a niche oncology startup in 2024 to bolster its pipeline in rare cancers. Regulatory updates, including the FDA’s 2023 expansion of Pemetrexed’s approved indications for advanced mesothelioma, have reshaped treatment protocols. Meanwhile, the market has seen a surge in demand for combination therapies, pairing Pemetrexed with immunotherapies to enhance efficacy, driven by promising clinical trial data. Consumer trends highlight a shift toward personalized treatment plans, supported by biomarker-driven diagnostics. Funding rounds have also accelerated, with venture capital firms injecting $150M in 2024 into digital health platforms integrating AI for Pemetrexed dose optimization, signaling a long-term pivot toward precision oncology.

Analyst Overview

The Pemetrexed Injection market outlook remains robust, driven by rising demand in oncology for non-small cell lung cancer and mesothelioma treatments. Market attractiveness is bolstered by favorable reimbursement policies in developed regions and a growing aging population. However, competitive intensity is moderate, with key players like Eli Lilly dominating through branded products, while generics may gain traction post-patent expirations. Long-term growth hinges on expanded indications and combination therapies, supported by ongoing R&D in precision oncology. The innovation landscape highlights advancements in formulation technologies to enhance drug stability and reduce side effects. Currently, demand-supply balance is stable, though potential shortages may arise if production scales to meet emerging market needs. Key risk factors include regulatory scrutiny over safety profiles, pricing pressures in cost-sensitive markets, and the threat of biosimilars disrupting market share. Strategic partnerships and geographic diversification will be critical for sustaining growth.

11 items

1. Executive Summary

2. Pemetrexed Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pemetrexed Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pemetrexed Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Non Squamous Non-Small Cell Lung Cancer

6.1.2. Squamous Cell Non-Small Cell Lung Cancer

6.2. Global Pemetrexed Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 0.5g Bottle

6.2.2. 0.2g Bottle

6.3. Global Pemetrexed Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pemetrexed Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pemetrexed Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pemetrexed Injection Market Competition by Key Manufacturers

8.1. Global Pemetrexed Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pemetrexed Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Eagle Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AuroMedics Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Teva Pharmaceutical Industries

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Taro Pharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Seacross Pharmaceuticals

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Simcere Pharmaceutical Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Qilu Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Pfizer

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Jiangsu Anda Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Yangtze River Pharmaceutical Group

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hansoh Pharmaceutical Group Company

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Nanjing Pharmaceutical Factory

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. DEYAO PHARMA

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Vianex S.A.-Plant C

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Hainan Jinrui Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pemetrexed Injection Market

Figure 4: Global Pemetrexed Injection Market: Drivers

Figure 5: Global Pemetrexed Injection Market: Challenges

Figure 6: Global Pemetrexed Injection Market: Trends

Figure 7: Global Pemetrexed Injection Market: Opportunity

Figure 8: Global Pemetrexed Injection Market: Restraint

Figure 9: Global Pemetrexed Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pemetrexed Injection Market Value (USD Million) By Region

Figure 15: Global Pemetrexed Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pemetrexed Injection Market Value (USD Million) By Region

Figure 23: Global Pemetrexed Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Pemetrexed Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pemetrexed Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pemetrexed Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pemetrexed Injection Market Value (USD Million) By Region

Table 10: Global Pemetrexed Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pemetrexed Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pemetrexed Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pemetrexed Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Eagle Pharmaceuticals Basic Information And Sales Area

Table 31: Eagle Pharmaceuticals. Products Portfolio

Table 32: AuroMedics Pharma Basic Information And Sales Area

Table 33: AuroMedics Pharma. Products Portfolio

Table 34: Teva Pharmaceutical Industries Basic Information And Sales Area

Table 35: Teva Pharmaceutical Industries. Products Portfolio

Table 36: Taro Pharma Basic Information And Sales Area

Table 37: Taro Pharma. Products Portfolio

Table 38: Seacross Pharmaceuticals Basic Information And Sales Area

Table 39: Seacross Pharmaceuticals. Products Portfolio

Table 40: Simcere Pharmaceutical Group Basic Information And Sales Area

Table 41: Simcere Pharmaceutical Group. Products Portfolio

Table 42: Qilu Pharmaceutical Basic Information And Sales Area

Table 43: Qilu Pharmaceutical. Products Portfolio

Table 44: Pfizer Basic Information And Sales Area

Table 45: Pfizer. Products Portfolio

Table 46: Jiangsu Anda Pharmaceutical Basic Information And Sales Area

Table 47: Jiangsu Anda Pharmaceutical. Products Portfolio

Table 48: Yangtze River Pharmaceutical Group Basic Information And Sales Area

Table 49: Yangtze River Pharmaceutical Group. Products Portfolio

Table 50: Hansoh Pharmaceutical Group Company Basic Information And Sales Area

Table 51: Hansoh Pharmaceutical Group Company. Products Portfolio

Table 52: Nanjing Pharmaceutical Factory Basic Information And Sales Area

Table 53: Nanjing Pharmaceutical Factory. Products Portfolio

Table 54: DEYAO PHARMA Basic Information And Sales Area

Table 55: DEYAO PHARMA. Products Portfolio

Table 56: Vianex S.A.-Plant C Basic Information And Sales Area

Table 57: Vianex S.A.-Plant C. Products Portfolio

Table 58: Hainan Jinrui Pharmaceutical Basic Information And Sales Area

Table 59: Hainan Jinrui Pharmaceutical. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Pemetrexed Injection Market Value (USD Million) By Region

Table 65: Global Pemetrexed Injection Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pemetrexed Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Eagle Pharmaceuticals; AuroMedics Pharma; Teva Pharmaceutical Industries; Taro Pharma; Seacross Pharmaceuticals; Simcere Pharmaceutical Group; Qilu Pharmaceutical; Pfizer; Jiangsu Anda Pharmaceutical; Yangtze River Pharmaceutical Group; Hansoh Pharmaceutical Group Company; Nanjing Pharmaceutical Factory; DEYAO PHARMA; Vianex S.A.-Plant C; Hainan Jinrui Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options